Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (12501)	8/3/1998 12:38:00 AM
From: AlienTech	Read Replies (1) \| Respond to of 23519

>>So in fact "institutional" ownership is up 3% from mid June. << Leyland must have bought a few more shares for a raining day.

To: VLAD who wrote (12501)	8/3/1998 1:09:00 AM
From: AlienTech	Respond to of 23519

You think some of these funds are still in VVUS? RE:OXHP Last year high 80+, Currently 7 1/2 But following that smart money has not led the average investor to more riches, and the stock does not strike many as a bargain even at its low, low levels today. Price's group, Franklin Mutual Advisers, which bought about 4.2 million shares late last year, has apparently seen the value of its investment dwindle, and it declined to say whether it still owned that stake. The other big shareholders, Texas Pacific and Dr. Norman C. Payson, Oxford's new chief executive, are well insulated from the effects of any bad news when the company reports its second-quarter results in mid-August. Under the deal struck by Texas Pacific, the price of its stake depends on the stock's price next year. Even Payson, who plunked down $10 million of his hard-earned money for Oxford's stock -- at $15.52 a share -- stands to get options on 1 million shares based on the price at the time of the company's annual meeting in late August. His options on 2 million more shares can be exercised at $15.52.